Overview
HCM market data
Price History
HCM price chart
Valuation & Profitability
- P/E (TTM)
- 4.74 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.52 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.16 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 83.3% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $15.57 – $28.80 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $17B · P/B 1.84 · P/S 3.95.
Company News
HUTCHMED (China) H1 EPS $0.09 Down From $2.61 YoY, Sales $278.287M Up From $277.677M YoYBenzinga · Jul 30, 2026, 11:00 AM
Goldman Sachs Maintains Neutral on HUTCHMED (China), Lowers Price Target to $14Benzinga · Jul 23, 2026, 4:15 PM
B of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $17Benzinga · Jul 7, 2026, 2:35 PM
HUTCHMED's Experimental Drug Shows Durable Responses In Advanced Bile Duct Cancer TrialBenzinga · Jun 25, 2026, 4:15 PM
Johnson & Johnson Hits Target With IMAAVY In Rare Blood DisorderBenzinga · Jun 11, 2026, 5:15 PM